Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Sanofi’s Praluent Closes Gap On Repatha In Europe, As GSK Gets Green Light For World’s First Malaria Vaccine

This article was originally published in The Pink Sheet Daily

Executive Summary

Europe’s CHMP grants positive opinions for Sanofi’s Praluent and GSK’s not-for-profit malaria vaccine Mosquirix at July meeting; other products recommended include Shire’s Intuniv, Merck’s Zerbaxa, Basilea’s Cresemba and Keryx’s Fexeric.

Advertisement

Related Content

Sun Partners Indian Research Agency For ‘Malaria-Free’ Initiative
Aegerion’s Lojuxta Submission To Germany's IQWIG Disappoints
Deal Watch: Boehringer’s Busy Week – An Acquisition, A Divestiture And A Discontinuation
Praluent Launch Brings Clinical Practice Challenges
Broad Enough? Sponsors Pleased With Narrower Praluent Label
Astellas Cresemba Clears FDA For Orphan, But Not Limited, Populations
Basilea Recovers With Astellas Deal For Phase III Anti-Fungal Following J&J Break-Up

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS078736

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel